Bob Ragusa, Grail CEO
#ESMO22: Grail puts its cancer test to a real world trial — but it's 'not ready for prime time yet'
PARIS — The centerpiece of Illumina’s controversial $8 billion Grail buyout — OK’ed in the US but swatted down in the EU — is the cancer test, Galleri.
According to Grail, Galleri can detect over 50 kinds of cancers before people even show symptoms. It has been sold in the US for $949 since last year (sans FDA approval, as the FDA chooses not to regulate so-called laboratory-developed tests), but comes with its fair share of concerns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
